- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03529006
Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Absorb ISR is randomized-controlled trial of Absorb scaffold vs. Sequent Please drug coated balloon in an all-comers population with in-stent-restenosis. The patients will be randomized in a 1:1 fashion and the investigators intend to include 150 patients.
Repeat coronary angiography will be performed 9 months post intervention in all subjects. Optical coherence tomography will be performed at baseline and at 9 months in both groups.
All patients presenting with ISR and requiring percutaneous coronary intervention will be eligible to be included in this study. This will include patients with stable angina and those presenting with acute coronary syndrome (ACS).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- Diagnosed with ISR requiring percutaneous coronary intervention: visual diameter stenosis > 70 % and/or Fractional Flow Reserve < 0.81 and/or non-invasive testing demonstrating ischemia. This real-life population with in-stent restenosis beside typical stable patients with ISR includes ACS patients with thrombus containing lesions, patients with multivessel disease, patients with ISR in non-infarct related artery, with ISR in BMS (bare metal stent), DES (drug eluting stent) or BVS, ISR in lesion previously treated by POBA (plain old balloon angioplasty), DEB or additional stent implantation.
- Double anti-platelet therapy for the duration of at least 12 months is considered possible at the time of intervention.
Exclusion Criteria:
- Difficulty with deliver and implant the Absorb scaffold (e.g. highly calcified lesions).
- Patients who have any contraindications for using DEB (SeQent Please) or BVS (Absorb).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sequent Please Drug Coated Balloon Group
For Sequent Please Group, PCI (percutaneous coronary intervention) PCI procedure with Sequent Please inflation will be performed - drug eluting balloon will be used in the narrowed part of the artery.
This method of treatment is one of the standard ones, which is typically used for treatment patients with diagnosis of in stent restenosis, the exact intervention and anesthesia procedures will be performed according to physician's usual practice.
For bailout situation Xience stent implantation is possible.
|
PCI procedure for treatment of ISR with DEB - Sequent Please - inflation
|
Active Comparator: Absorb Stent Group
Absorb scaffold group will be treated by PCI procedure with Absorb BVS implantation - implantation of bioresorbable vascular scaffold (Absorb).
Coronary stent implantation for treatment in stent restenosis is one of the standard method of treatment this disease, but Absorb system has not been investigated in this indication yet.
|
PCI procedure for treatment of ISR with Absorb BVS implantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Angiographic late lumen loss at 9 months
Time Frame: 9 months
|
Late lumen loss will be calculated based on index and control coronary angiography.
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
- Incidence of periprocedural complications: unplanned use of GP IIb/IIIa (Glycoprotein IIb/IIIa) inhibitors, vessel rupture, side branch occlusion, peri-procedural myocardial infarction
Time Frame: 9 months
|
Periprocedural complications will be analyzed as combined endpoint and separately for all defined complication.
|
9 months
|
- Comparison of rate of restenosis between both groups and in specific populations (patients with acute coronary syndromes, patients with diabetes, patients with long lesions (> 25 mm))
Time Frame: 9 months
|
The angiographic parameter will be compared separately in all defined subgroups.
|
9 months
|
- Comparison of minimal luminal diameter between both groups and in specific populations (patients with acute coronary syndromes, patients with diabetes, patients with long lesions (> 25 mm))
Time Frame: 9 months
|
The angiographic parameter will be compared separately in all defined subgroups.
|
9 months
|
- Comparison of diameter stenosis between both groups and in specific populations (patients with acute coronary syndromes, patients with diabetes, patients with long lesions (> 25 mm))
Time Frame: 9 months
|
The angiographic parameter will be compared separately in all defined subgroups.
|
9 months
|
- Incidence of in-stent-restenosis, target lesion failure, target vessel revascularisation, stent thrombosis in in-hospital and long-term observation
Time Frame: 9 months
|
Four clinical complications will be compared separately between study groups.
|
9 months
|
- Early, late and very late probable or definite stent thrombosis
Time Frame: 9 months
|
Detailed description of all events of stent thrombosis will be presented.
|
9 months
|
- Cardiac and non-cardiac death in both groups
Time Frame: 9 months
|
The frequency of deaths in both study group will be presented with differentiation according to the primary cause of the event.
|
9 months
|
- Assessment of possibility vessel measurement and stent diameter/length choice based on this measurement performed in OCT (Optical Coherence Tomography)
Time Frame: During index procedure.
|
The usefulness of OCT for stent choice will be analyzed.
The frequency of procedures, when stent choice was done based on OCT measurements will be presented.
|
During index procedure.
|
- Result of index procedure assessment in OCT post procedure - lumen area.
Time Frame: During index procedure.
|
The OCT parameter describing of stent implantation result during index procedure will be compared between study groups.
|
During index procedure.
|
- Result of index procedure assessment in OCT post procedure - stent area.
Time Frame: During index procedure.
|
The OCT parameter describing of stent implantation result during index procedure will be compared between study groups.
|
During index procedure.
|
- Result of index procedure assessment in OCT post procedure - struts apposition assessment.
Time Frame: During index procedure.
|
The OCT parameter - frequency of strut malapposition - describing of stent implantation result during index procedure will be compared between study groups.
|
During index procedure.
|
- Result of index procedure assessment in OCT post procedure - dissections.
Time Frame: During index procedure.
|
The OCT parameter describing of stent implantation result during index procedure will be compared between study groups.
|
During index procedure.
|
- Result of index procedure assessment in OCT post procedure - stent expansion index.
Time Frame: During index procedure.
|
The OCT parameter describing of stent implantation result during index procedure will be compared between study groups.
|
During index procedure.
|
- OCT assessment of long-term study results - lumen area.
Time Frame: 9 months
|
The OCT parameter describing of stent implantation result in long term FU (follow-up) will be compared between study groups.
|
9 months
|
- OCT assessment of long-term study results - stent area.
Time Frame: 9 months
|
The OCT parameter describing of stent implantation result in long term FU (follow-up) will be compared between study groups.
|
9 months
|
- OCT assessment of long-term study results - struts apposition assessment.
Time Frame: 9 months
|
The OCT parameter describing of stent implantation result in long term FU (follow-up) will be compared between study groups.
|
9 months
|
- OCT assessment of long-term study results - neointimal volume.
Time Frame: 9 months
|
The OCT parameter describing of stent implantation result in long term FU (follow-up) will be compared between study groups.
|
9 months
|
- OCT assessment of long-term study results - lumen volume.
Time Frame: 9 months
|
The OCT parameter describing of stent implantation result in long term FU (follow-up) will be compared between study groups.
|
9 months
|
- Lumen volume change between index and 9M (nine months) FU in OCT.
Time Frame: 9 months
|
The change of OCT parameter describing of stent implantation result will be compared between index procedure and in long term FU for both study groups.
|
9 months
|
- Minimal lumen area change between index and 9M (nine months) FU in OCT.
Time Frame: 9 months
|
The OCT parameter describing of stent implantation result will be compared between index procedure and in long term FU for both study groups.
|
9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Florim Cuculi, Luzerner Kantonsspital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- AbsorbISR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on In-stent Restenosis
-
Assiut UniversityNot yet recruiting
-
Fundación Médica para la Investigación y Desarrollo...Abbott Medical Devices; Hospital San Carlos, Madrid; B.Braun Surgical SAUnknown
-
Cordis CorporationCompletedIn-Stent RestenosisUnited States
-
Boston Scientific CorporationActive, not recruiting
-
Klinikum CoburgUnknown
-
Seoul National University HospitalUnknownIn-stent Restenosis LesionKorea, Republic of
-
Midwest Cardiovascular Research FoundationCompletedFemoropopliteal In-stent RestenosisUnited States
-
Spanish Society of CardiologyAbbott Medical Devices; Terumo Medical Corporation; Fundación de Investigación... and other collaboratorsUnknownCoronary In-stent RestenosisSpain
-
Spectranetics CorporationYale UniversityWithdrawnFemoropopliteal In-Stent RestenosisColombia
-
Second Affiliated Hospital, School of Medicine,...West China Hospital; The Third Xiangya Hospital of Central South University; Shanghai... and other collaboratorsUnknownCoronary In-stent RestenosisChina
Clinical Trials on Sequent Please inflation
-
SIS Medical AGSuspendedCoronary Artery Disease | Coronary RestenosisSwitzerland
-
University Hospital, SaarlandCompletedCoronary Heart Disease | NSTEMIGermany
-
Korea University Ansan HospitalB. Braun Korea Co., Ltd.RecruitingCoronary Artery Disease | De Novo Stenosis | Atherosclerotic PlaqueKorea, Republic of
-
Ralf Degenhardt, PhDB. Braun Melsungen AGCompletedCoronary Heart DiseasesIndia
-
DK Medical Technology (Suzhou) Co., Ltd.Core Medical (Beijing) Co., Ltd.Active, not recruitingCoronary In-stent RestenosisChina
-
Fundación EPICRecruiting
-
JW Medical Systems LtdActive, not recruitingCoronary Artery DiseaseChina
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Chonnam National University Hospital; Ulsan... and other collaboratorsUnknownCoronary Artery DiseaseKorea, Republic of
-
Shanghai MicroPort Medical (Group) Co., Ltd.Recruiting
-
B. Braun Medical Industries Sdn. Bhd.Seoul National University Hospital; Ulsan University Hospital; European Cardiovascular... and other collaboratorsRecruitingMyocardial Ischemia | Coronary Artery Disease | Acute Coronary Syndrome | Coronary Stenosis | De Novo StenosisMalaysia, Taiwan, Korea, Republic of, Singapore